Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069594 | 0.88 | PPARA (0.56) | PPARAPPARGPPARDCHRM4KDM4E | |
| SCHEMBL2069538 | 0.88 | PPARA (0.56) | PPARAPPARGPPARDCHRM4KDM4E | |
| SCHEMBL2069070 | 0.88 | PPARA (0.56) | PPARAPPARGPPARDCHRM4KDM4E | |
| SCHEMBL5189321 | 0.84 | PPARA (0.72) | PPARAPPARGPPARDCHRM4KDM4E | |
| SCHEMBL14528288 | 0.83 | PPARA (0.58) | PPARAPPARGPPARD | |
| SCHEMBL2069706 | 0.83 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL5193737 | 0.83 | PPARA (0.52) | PPARAPPARGPPARDCHRM4MAPT | |
| SCHEMBL5193735 | 0.83 | PPARA (0.52) | PPARAPPARGPPARDCHRM4MAPT | |
| SCHEMBL2069318 | 0.83 | PPARA (0.56) | PPARAPPARGPPARDMAPTLMNA | |
| SCHEMBL2069034 | 0.83 | PPARA (0.73) | PPARAPPARGPPARDCHRM4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-7902367-B2 | Cyclic amino benzoic acid derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| CN-101014595-A | Novel cyclic aminobenzoic acid derivative | KYORIN SEIYAKU KK (JP) | 2007-08-08 | — | — | CN | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
| EP-1780210-A1 | NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2007-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249580-A1 | Novel Cyclic Amino Benzoic Acid Derivative | PPARA, PPARG, PPARD | PPARA 1/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.